<DOC>
	<DOCNO>NCT03006198</DOCNO>
	<brief_summary>The objective study explore describe disease characteristic , treatment outcome participant rheumatoid arthritis , ankylose spondylitis , psoriatic arthritis , Crohn 's Disease ulcerative colitis major disease treat REMICADE , SIMPONI STELARA clinical practice emerge region North Africa , Middle East , Western Asia .</brief_summary>
	<brief_title>Tracking Biologics Along Silk Road</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<criteria>Participant must confirm diagnosis rheumatoid arthritis , ankylose spondylitis , psoriatic arthritis , Crohn 's Disease , ulcerative colitis . A participant include one disease ; participant multiple diagnosis include major disease Initiation treatment REMICADE , SIMPONI , STELARA plan time enrollment observational study ( treatment start within 30 day enrollment ) Participant must either treatmentna√Øve biologics treat 2 different biologic agent enrollment Participant must sign participation agreement/informed consent form ( ICF ) allow data collection source data verification accordance local requirement Participant previously receive treatment REMICADE , SIMPONI , STELARA must enrol start therapy second time Participant receive investigational drug ( include investigational vaccine ) use invasive investigational medical device within 30 day baseline data collection Participant currently enrol investigational study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>